General of the Environment and Natural Resources Division, Department of Justice, P.O. Box 7611, Washington, D.C. 20044. Comments should refer to *United States of America* v. *ASARCO, Incorporated,* DOJ Ref. #90–5–1–1–4113.

The proposed consent decree may be examined at the office of the United States Attorney, Zorinsky Federal Building, 214 N. 17th Street, Omaha, Nebraska; the Region VII Office of the Environmental Protection Agency, 726 Minnesota Avenue, Kansas City, Kansas; and at the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, DC 20005, (202) 624–0892. A copy of the proposed Consent Decree may be obtained in person or by mail from the Consent Decree Library.

In requesting a copy, please enclose a check in the amount of $8.50 (25 cents per page reproduction cost) payable to the ''Consent Decree Library.''

Bruce Gelber,

Acting Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95–17136 Filed 7–12–95; 8:45 am]

BILLING CODE 4410–01–M

Notice of Lodging of Consent Decree Pursuant to the Resource Conservation and Recovery Act

In accordance with Departmental policy, 28 C.F.R. 50.7, notice is hereby given that a proposed consent decree in *United States* v. *Lacks Industries, Inc.*, Case No. G87–413CA, was lodged on with the United States District Court for the Western District of Michigan on June 29, 1995. The proposed consent decree resolves civil claims brought against Lacks Industries, Inc. (''Lacks'') under the Resource Conservation and Recovery Act, as amended, 42 U.S.C. 6901 *et seq*., relating to a Saranac, Michigan facility owned and operated by Lacks. The decree requires Lacks: (1) to cease treatment or disposal of additional hazardous waste at its Saranac facility except in accordance with applicable standards for hazardous waste generators and treatment, storage or disposal facilities; (2) to close hazardous waste management units at its Saranac facility in accordance with a closure plan approved by Michigan Department of Natural Resources (''MDNR''), and to provide post-closure care if waste residues are not completely removed or decontaminated as part of the closure process; (3) to provide financial assurances for closure and post-closure care of the Saranac facility; (4) to comply with liability coverage requirements for sudden and non-sudden occurences at the Saranac facility, in accordance with specified regulations; (5) to install and maintain a groundwater monitoring system at the Saranac facility and monitor groundwater in accordance with a groundwater quality assessment plan approved by MDNR and other applicable requirements; (6) to initiate corrective action at the Saranac facility by performing a RCRA Facility Investigation and Corrective Measures Study in accordance with work plans approved by U.S. EPA; and (7) to pay a $250,000 civil penalty previously assessed by the court in the above-referenced civil action against Lacks. The consent decree specifically reserves the right of the United States to assert additional claims to require Lacks to perform any corrective action measures which U.S. EPA selects following completion of the RCRA Facility Investigation and Corrective Measures Study.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, D.C. 20530, and should refer to *United States* v. *Lacks Industries, Inc.*, Case No. G87–413CA and the Department of Justice Reference No. 90–7–1–360.

The proposed consent decree may be examined at the Office of the United States Attorney, Western District of Michigan, 399 Federal Building, 110 Michigan St. NW, Grand Rapids, Michigan, and at U.S. EPA Region 5, Office of Regional Counsel, 200 West Adams, Chicago, Illinois; and at the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, D.C. 20005, 202–624–0892. A copy of the proposed consent decree may be obtained in person or by mail from the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, D.C. 20005. In requesting a copy, please refer to the referenced case and enclose a check in the amount of $17.75 (25 cents per page reproduction costs), payable to the Consent Decree Library.

Bruce S. Gelber,

Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95–17177 Filed 7–12–95; 8:45 am]

BILLING CODE 4410–01–M

Notice of Lodging of Consent Decree Pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA)

In accordance with Departmental policy, 28 C.F.R. 50.7, and 42 U.S.C. 9622(d)(2), notice is hereby given that a proposed consent decree in *United States* v. *Monsanto Company, et al.*, Civil Action No. 3:92–0961–19, was lodged on July 3, 1995, with the United States District Court for the District of South Carolina. This agreement resolves a judicial enforcement action brought by the United States against the defendants pursuant to Section 107 of the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. 9607, for the recovery of response costs incurred and to be incurred by the United States in connection with the Dixiana Superfund Site (''Site'') located in Lexington County, South Carolina.

Under the proposed Consent Decree, the United States has obtained 84.5 percent of its past response costs, including prejudgment interest, totaling $4,132,837, and has obtained a commitment for payment of all EPA's future oversight costs. The Settling Defendants will also assume full responsibility for upgrading and completing the remedy initiated at the Site by EPA.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, D.C. 20530, and should refer to *United States* v. *Monsanto Company, et al.*, DOJ Ref. #90–11–3–336.

The proposed consent decree may be examined at the office of the United States Attorney, 1st Union Building, 1441 Main Street, Suite 500, Columbia, South Carolina; the Region IV Office of the Environmental Protection Agency, 345 Courtland Street, N.E., Atlanta, Georgia; and the Consent Decree Library, 1120 G. Street, N.W., 4th Floor, Washington, D.C. 20005, (202) 624–0892. A copy of the proposed consent decree may be obtained in person or by mail from the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, D.C. 20005. In requesting a copy please refer to the referenced case and enclose a check in the amount of $20.25 (25 cents per page reproduction

costs), payable to the Consent Decree Library.

Bruce Gelber,

Acting Chief, Environmental Enforcement Section, Environmental and Natural Resources Division.

[FR Doc. 95–17176 Filed 7–12–95; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 18, 1995, Applied Science Labs, Division of Alltech Associates, Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
4-Methylaminorex (cis isomer) (1590)	I
Lysergic acid diethylamide (7315)	I
Mescaline (7381)	I
3,4-Methylenedioxyamphetamine (7400)	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I
3,4-Methylenedioxymethamphetamine (7405)	I
N-Ethyl-1-phenylcyclohexylamine (7455)	I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
1-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
Phenylacetone (8501)	II
1-Piperidinocyclohexanecarbonitrile (8603)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Benzoylecgonine (9180)	II
Morphine (9300)	II
Oxymorphone (9652)	II

The firm plans to manufacture small quantities of these controlled substances for reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than August 14, 1995.

Dated: July 5, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–17118 Filed 7–12–95; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with § 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on May 18, 1995, Applied Science Labs, Division of Alltech Associates, Inc., 2701 Carolean Industrial Drive, P.O. Box 440, State College, Pennsylvania 16801, made application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Heroin (9200)	I
Morphine (9300)	II

The firm plans to import these controlled substances for the manufacture of reference standards.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of these basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed in 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than August 14, 1995.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR